Ponesimod Patent Expiration
Ponesimod is used for reducing circulating lymphocytes in treating relapsing forms of multiple sclerosis in adults. It was first introduced by Vanda Pharmaceuticals Inc
Ponesimod Patents
Given below is the list of patents protecting Ponesimod, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Ponvory | US11951097 | Methods of treating multiple sclerosis | Oct 10, 2042 | Vanda Pharms Inc |
| Ponvory | US10220023 | Dosing regimen for a selective S1P1 receptor agonist | Dec 10, 2035 | Vanda Pharms Inc |
| Ponvory | US9062014 | Crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-0-tolyl-thiazolidin-4-one | May 06, 2032 | Vanda Pharms Inc |
| Ponvory | US8273779 | Thiazolidin 4-one derivatives | Dec 17, 2025 | Vanda Pharms Inc |
| Ponvory | USRE43728 | Thiazolidin-4-one derivatives | Nov 16, 2025 | Vanda Pharms Inc |
| Ponvory | US9000018 | Thiazolidin-4-one-derivatives |
Nov 16, 2024
(Expired) | Vanda Pharms Inc |
| Ponvory | USRE43728 | Thiazolidin-4-one derivatives |
Nov 16, 2024
(Expired) | Vanda Pharms Inc |
Ponesimod's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List